As nanomedicine-based clinical strategies have continued to develop, the possibility of combining chemotherapy and singlet oxygen-dependent photodynamic therapy (PDT) to treat pancreatic cancer (PaC) has emerged as a viable therapeutic modality. The efficacy of such an approach, however, is likely to be constrained by the mechanisms of drug release and tumor oxygen levels.
Introduction
Pancreatic cancer (PaC) is among the most common forms of cancer [1] , and yet it remains extremely deadly, with a very poor prognosis [2] . Approximately ¼ of PaC cases are first diagnosed when the disease is advanced and surgical resection is ineffective, at which point only palliative chemotherapy has been found to improve quality of life and extend survival [3, 4] . Chemotherapeutic drugs, however, are associated with severe side effects and most patients inevitably have difficulty to lerating treatment regimens, eventually discontinuing treatment [5] . As such, the development of novel effective and safe PaC treatment modalities remains a research imperative. Recent developments in the field of nanomedicine have offered potential opportunities for such treatments through the use of strategies such as nanocarriers, singlet oxygen-dependent photodynamic therapy (PDT) and combinations of these technologies and other treatments [6] . Nanocarriers can significantly improve tumor accumulation and reduce side effect through enhanced permeability and retention (EPR) effect and stimulus response methods [7] [8] [9] [10] [11] [12] . These approaches often employ a specific release mechanism to ensure that premature drug release does not occur outside of the tumor, with methods such as light-sensitive nanocarriers allowing for effective release of chemotherapeutic drugs in tumors upon noninvasive laser irradiation, thereby mediating specific tumor cell necrosis and apoptosis in a manner that can overcome drug resistance [13, 14] , prolonging median survival time in those with locally advanced PaC [15] .
While the combination of chemotherapy and PDT has shown promising synergistic efficacy, therapeutic outcomes are still limited by the relatively poor production of reactive oxygen species (ROS) within the PaC tumors [16] . This occurs in part due to limited oxygen as a result of factors including unconstrained tumor cell growth and abnormal vasculature formation [17] , with PDT-induced microvascular collapse further reducing the local O2 supply and aggravating hypoxia within the tumor [18] [19] [20] . Multiple studies have sought to improve PDT therapeutic outcomes via overcoming the hypoxic state of tumors [21, 22] . One strategy that has often been employed relies upon the use of nanoscale oxygen carriers including perfluorocarbon nanodroplets [23] , calcium peroxide nanocomplexes [24] , and oxygen carrying microbubbles [25] to deliver oxygen directly to the tumor. However, a more efficient strategy is one that promotes specific oxygen production within the tumor microenvironment (TME). As cells progress towards malignancy, they become capable of producing increasingly large quantities of hydrogen peroxide (H2O2) at local levels as high as 100 × 10 −6 M-1 × 10 −3 M within the TME [26, 27] . As such, nanoplatforms capable of encouraging O2 generation within the TME, including carbon nitride [28, 29] , MnO2 nanoparticles [30] and catalase [16] , represent an ideal means of converting this H2O2 into O2 as a means of overcoming hypoxia. This O2 can then be converted into the cytotoxic singlet oxygen ( 1 O2) upon light irradiation, thus significantly enhancing local PDT efficacy [30, 31] . In a recent report, Lan et al. developed a nanoscale metal−organic framework (MOF) made up of a combination of Fe3O clusters and 5,10,15,20-tetra(pbenzoato)porphyrin (TBP), producing particles capable of catalyzing the conversion of H2O2 into O2 via an irondependent Fenton-like reaction, thereby improving local PDT efficacy and reducing tumor hypoxia in a murine model of colorectal cancer upon in situ injection [32] . In addition to its promising efficacy, this study highlights a viable strategy for reducing local hypoxia and promoting effective chemotherapy and PDT combination treatment of PaC.
In the present study, we sought to develop an approach suited to overcoming hypoxic conditions within PaC tumors in order to improve combination therapeutic efficiency. To this end, we combined Fe 3+ with FDA-approved photosensitizer porphyrins in order to generate a porous coordination network (PCN) that could then be loaded with the chemotherapeutic agent paclitaxel (PTX), thereby generating PCN-Fe(III)-PTX nanoparticles (NPs) ( Fig. 1(a) ). Fe(III) ions were used because they offer dual utility as both a catalyst for Fenton-like reactions, and a as a contrast agent for T1-weighted magnetic resonance imaging (MRI), allowing for monitoring of tumor therapeutic responses. As the PCN structure is unstable in the lower pH of the TME, and is further destabilized upon heating in response to 671 nm laser irradiation, these NPs were able to effectively release PTX in response to both pH changes and irradiation in tumor bearing mice, thereby markedly improving the combination PDT and chemotherapeutic efficacy. In summary, the results of this in vitro and in vivo study suggest that PCN-Fe(III)-PTX NPs are an ideal nanocarrier capable of generating local O2 production in the TME, overcoming tumor-associated hypoxia and thereby improving outcomes in response to combination PDT-chemotherapy.
Materials and methods

Materials
Ferric chloride, tetrakis (4-carboxyphenyl)-porphine, Ti(SO4)2, N,N-dimethylformamide (DMF), FITC phalloidin, MAK164 and 1,3-diphenylisobenzofuran were purchased from Sigma-Aldrich (Shanghai, China). Cell counting kit-8 (CCK-8) and PTX were purchased from Med Chem Express (Monmouth Junction, NJ, USA). Hoechst and FeCl3 were purchased from Aladdin Industrial Inc. (Shanghai, China). The Calcein-AM/PI kit was purchased from Yeasen Biological Technology Co., Ltd. (Shanghai, China). Ti(SO4)2 was purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). Deionized water (Millipore Milli-Q; 18.2 MΩ) was used for all studies. No further chemical purification was performed.
Cell lines and animals
The human pancreatic cancer PANC-1 line was obtained from the Shanghai Gefan Biotechnology. Co. (Shanghai, China) and grown in Dulbecco modified Eagle medium (DMEM) (Hyclone, USA) containing 10% fetal bovine serum (FBS) (Hyclone) at 37 °C in an incubator under 5% CO2 conditions. For in vivo studies, 5-6 week old nude mice from BiKai Biological products sales center (Nanjing, China) were used, with protocols having been approved by the Regional Ethics Committee for Animal Experiments at Ningbo University (Permit No. SYXK Zhe 2013-0191). 
PCN-Fe(III)-PTX synthesis
A 30 mL volume of DMF was used for dissolving ferric chloride and tetrakis (4-carboxyphenyl)-porphine at a 3:1 molar ratio, and solids were dissolved via 10 min of sonication. Next, 3 mL of formic acid was injected into the solution followed by an additional 10 min of sonication, after which the solution was transferred to a PTFE liner and stored for 24 h at 80 °C in order to generate PCN-Fe(III). Samples were then cooled to room temperature, washed thrice with anhydrous ethanol, and freezedried overnight. To generate the final PCN-Fe(III)-PTX, 10 mg of PCN-Fe(III) was stirred for 24 h with 10 mg of PTX in 10 mL dichloromethane. The resultant NPs were spun at 13,000 rpm for 10 min, washed, and freeze-dried until use.
Measuring H 2 O 2 catalytic activity
First, a preparation of Ti(SO4)2 was created via diluting 8.33 mL H2SO4 to a final 50 mL volume with deionized water, after which 50 mg Ti(SO4)2 was added. This solution was used for a colorimetric assay in which mixing different concentrations of 0.35 mL H2O2 (97.17 μM) and 2.65 mL Ti(SO4)2 was associated with a change in the yellow color of this solution that could be read as an absorption peak at 405 nm. H2O2 catalytic ability was measured by mixing 97.17 μM H2O2 at 37 °C with 5 μM PCN-Fe(III) in 0.35 mL deionized water. Samples were then spun and combined with 2.65 mL Ti(SO4)2, and absorbance was read after 0, 1, 3, 5, 10, 30, 60, 90, 120, 150, or 180 min.
Intracellular measurement of H 2 O 2 catalytic activity
MAK164 was used to probe cells for intracellular H2O2 levels. Briefly, after being cultured for 24 h on 96-well plates, PANC-1 cells were treated for an additional 24 h with either PBS, PCN-Fe(III), or PCN-Fe(III)-PTX (5 μM PCN-Fe(III)). Cells were then washed in PBS and 100 μL of 100 μM H2O2 in DMEM was added per well for 1 h. The fluorescent MAK164 probe was then added for an additional hour. Cells were then washed repeatedly in PBS, and intracellular H2O2 levels were assessed via fluorescence microscopy (Ex/Em = 490/520).
Singlet oxygen production
A mixture of 1 mL PCN-Fe(III) (5 μM) and 40 μL 1,3diphenylisobenzofuran (DPBF) (3 mM) underwent laser irradiation (100 mW/cm 2 671 nm) for 0, 10, 20, 30, 60, 120, 180, 300, 420, or 600 s, after which absorbance was measured at 405 nm.
Assessment of pH-dependent drug release and biocompatibility
A dynamic dialysis approach was used to gauge cumulative PTX release over time from the PCN-Fe(III)-PTX NPs [33] . For this approach, 1 mL of PCN-Fe(III)-PTX at 1 mg/mL was added to a dialysis bag with a 3.5 kDa MWCO, and samples were dialyzed at 100 rpm in an oscillating incubator. To the dialysis bags was added 0.01 M PBS and 0.5% polysorbate 80 at either a pH of 5.0 or 7.4. At appropriate time points, 0.5 mL of the sample was collected and replaced with an equivalent volume. High performance liquid chromatography (HPLC) was then used to assess PTX concentrations, which were used to calculate drug release dynamics. CCK-8 assays were used to gauge the biocompatibility of PCN-Fe(III) NPs based on their toxicity when used to treat PANC-1 cells. Briefly, after growing 5 × 10 3 cells/well overnight in 96-well plates, 100 μL PCN-Fe(III) (100, 75, 50, 25, 12.5, 6.25, or 0 μg/mL) was added to each well for an additional 24 h. Next, 10 μL of the CCK-8 solution was added per well, and HPLC was used to assess optical density in each well.
Cellular NPs uptake
In order to determine how readily cells took up the PCN-Fe(III) and PCN-Fe(III)-PTX NPs, we employed confocal laser scanning microscopy (CLSM). To this end, we grew 1 × 10 5 PANC-1 cells in a 2 mL volume in confocal culture dishes (NETS Co., USA) for 24 h, after which 100 μg/mL PBS, PCN-Fe(III), or PCN-Fe(III)-PTX were added for 8 h. Samples were then washed thrice in PBS and fixed for 30 min using 4% formaldehyde. Next, 0.1% triton was used to permeabilize cells for 5 min, and then 1.0% bovine serum albumin (BSA) was used for blocking. Cells were next stained at room temperature for 30 min with FITC phalloidin (5 μg/mL) and Hoechst 33258 Stain solution (10 μg/mL) prior to CLSM assessment. We additionally used flow cytometry to assess NP uptake using PANC-1 cells that had been grown in 6-well 0.01% poly (Lys)-coated plates (1 × 10 5 cells/well). After cells had adhered overnight, fresh media containing 100 μg/mL of PCN-Fe(III) or PCN-Fe(III)-PTX was added for 8 h, after which the cells were washed thrice with PBS, detached using trypsin-EDTA, and analyzed via flow cytometry (FACSCalibur, BD, USA).
MRI in vitro and in vivo
PCN-Fe(III)-PTX T1 relaxivity times were assessed at different NP concentrations (0.8, 0.4, 0.2, 0.1, 0.05, and 0.025 mg/mL) with a 1.5 T human clinical MR scanner (Ingenia 1.5 T, Philips, the Netherlands). Inductively coupled plasma optical emission spectroscopy (ICP-OES) was used to determine iron concentrations, with longitudinal (r1) and transverse (r2) relaxivities determined based upon the slope of the inverse relaxation times (1/T1 and 1/T2) at particular iron concentrations. For in vivo imaging, i.p. 6% chloral hydrate was used to anesthetize mice with PANC-1 tumors. Once 50 μL PBS or PCN-Fe(III)-PTX (1.0 mg/mL) had been injected, T1-weighted images were acquired using the same scanner after 24 h for in vivo experiments.
In vitro therapeutic efficacy
To assess how PANC-1 cells responded to NPs in vitro, these cells (5 × 10 4 cells/mL) were added to 96-well plates (100 μL/well) for 24 h, after which they were resuspended in 100 μL DMEM supplemented with PTX, PCN-Fe(III), or PCN-Fe(III)-PTX at a range of concentrations (40, 20, 10, 5 and 2.5 μM for PCN-Fe(III)) for 8 h. Samples were washed thrice in PBS, after which 100 μL DMEM was added back to wells. Cells then underwent laser irradiation (671 nm, 15 min) followed by a 16 h incubation. The following combinations of conditions were used: (1) PTX, (2) PCN-Fe(III)-PTX, (3) PCN-Fe(III)+laser, and (4) PCN-Fe(III)-PTX+laser. After the 16 h incubation, viability was assessed via 450 nm absorbance readings taken using a microplate reader.
Live/dead staining
A Calcein-AM/PI double stain kit was used to assess cells for live/dead staining. Briefly, a total of 100 μL PANC-1 cells (5 × 10 4 /mL) were plated for 24 h in 96-well plates, after which media was replaced with 100 μL DMEM containing free PTX, PCN-Fe(III), or PCN-Fe(III)-PTX (10 μM PCN-Fe(III)) for 8 h. Cells were then washed thrice using PBS and 100 μL media was added back to wells. Cells then underwent laser irradiation (671 nm, 15 min) followed by a 16 h incubation. The following combinations of conditions were used: (1) PTX, (2) PCN-Fe(III)-PTX, (3) PCN-Fe(III)+laser, and (4) PCN-Fe(III)-PTX+laser. The Calcein-AM/PI solution was then used to stain cells for 30 min at 37 °C, after which a fluorescent microscope was used for imaging.
In vivo assessment of NP distribution and biocompatibility
In order to assess the toxicity of these NPs in vivo, a total of 100 μL PCN-Fe(III) (5.0 mg/mL) or PBS was injected into healthy nude mice, who were monitored for weight or behavior changes over 21 days. At the end of this period, mice were euthanized and blood was collected for routine assessment, while organs (heart, liver, spleen, lung, and kidney) were fixed using 4% paraformaldehyde and H&E stained to assess PCN-Fe(III)-PTX toxivity. In other experiments, 15 nude mice were i.v. injected using 100 μL PBS or (5 mg/mL) PCN-Fe(III), and animals were euthanized at 4, 12, 24, or 28 h following injection to measure Fe(III) in the tumor and organs via ICP-OES. We additionally assessed PCN-Fe(III) in vivo distribution based on particle fluorescence with an In Vivo Imaging System (IVIS) spectrum pre-clinical in vivo imaging system (PerkinElmer, USA; excitation = 640 nm, emission = 710 nm). For these experiments, mice were i.v. injected using 100 μL PBS or (5 mg/mL) PCN-Fe(III) NPs and fluorescence intensity was assessed at specific time points. At 28 h following injection, animals were euthanized and the fluorescence of tumors and organs was assessed ex vivo.
In vivo anti-tumor efficacy
To explore the combination efficacy of these NPs in vivo, nude mice were implanted in the flank with 2 × 10 6 PANC-1 cells. Once the tumors grew to be 50-100 mm 3 in size, mice were randomized into 5 treatment groups, with 5 mice per group: free PTX, PCN-Fe(III)-PTX, PCN-Fe(III)+laser, PCN-Fe(III)-PTX+laser, and PBS groups. Mice were then intravenously injected with 100 μL of the appropriate compounds on day 0. Following a 24 h period, i.p. 6% chloral hydrate was used to anesthetize mice, and tumors underwent laser irradiation (671 nm, 300 mW/cm 2 , 15 min). Tumor growth was monitored using calipers every other day, with tumor volume calculated according to the formula: longer tumor dimension × shorter tumor dimension 2 /2. Animal body weight was assessed every two days. After a 14 day period, animals were euthanized and tumors were isolated and imaged. In addition, organs and tumors were H&E stained.
Pharmacokinetic measurements
To access NPs pharmacokinetics, 7-8 week old female Balb/C mice were i.v. injected with PTX (10 mg/kg) or PCN-Fe(III)-PTX (n = 3/group). Blood was then collected via retro-orbital bleeding of these mice after 3, 6, or 30 min, or after 1, 2, 4, 6, 12, 24, or 36 h into tubes coated in anticoagulant (BDEDTA, USA). Samples were spun at 4,500 rpm for 10 min, and supernatants (150-200 μL) were combined with an equal volume of acetonitrile solution to mediate plasma protein separation. After filtration through a 2.2 μm filter, samples were then accessed via HPLC.
Results and discussion
Preparation and characterization PCN-Fe(III)-PTX
We synthesized PCN-Fe(III)-PTX NPs in two steps within an aqueous solution. We initially synthesized nanoscale rice-shaped PCN-Fe(III) NPs ( Fig. 1(b) ), and these were then used to generate the final PCN-Fe(III)-PTX NPs through the combination of PCN-Fe(III) with PTX in DMF. We then assessed the ultraviolet (UV) absorbance spectra of PTX, PCN-Fe(III) and PCN-Fe(III)-PTX NPs via spectrophotometry, revealing typical absorption peaks at 422, 528, 567, and 654 nm ( Fig. 1(c) ).
Assessment of NP size and surface charge via dynamic light scattering revealed PCN-Fe(III) and PCN-Fe(III)-PTX to have respective mean diameters of 296.3 ± 21.4 nm and 317.2 ± 15.1 nm, and respective negative zeta charges of −15.6 ± 0.4 mV, and −20.2 ± 0.7 mV in PBS (Figs. 1(d) and 1(e)), confirming successful PTX loading. We found PTX loading rates to be up to 47.3% (17.9 mg PTX/20 mg PCN-Fe(III)) based on HPLC results. These NPs also had an iron content of 13.3% ± 0.3% according to ICP-OES, with the PCN-Fe(III) particles exhibiting clear iron signals in an X-ray photoelectron spectroscopy (XPS) spectrum, and with a 718.35 eV pre-edge feature consistent with PCN-Fe(III) having a trivalent iron center [34] (Fig. S1 in the ESM). X-ray diffraction (XRD) was performed to indicate the crystal structure of PCN-Fe(III) (Fig. S2 in the ESM). We also detected the Brunauer-Emmett-Teller (BET) N2 adsorption/ desorption of PCN-Fe(III) and the result was shown in Fig. S3 in the ESM. The N2 adsorption/desorption curve indicated that the PCN-Fe(III) has a porous structure, which is expected to be an excellent carrier for small molecule drugs.
Catalase-like activity and ROS generation in vitro
We next assessed the ability of PCN-Fe(III) and PCN-Fe(III)-PTX to achieve catalase-like activity and ROS generation in vitro, given that the Fe(III) within these NPs should be capable of catalyzing H2O2 decomposition in order to mediate O2 generation. Therefore we used two methods to verify the catalytic ability of PCN-Fe(III), decomposing H2O2 into O2. First, we conducted a standard curve (Figs. S4(a) and S4(b) in the ESM) and assessed remaining H2O2 via UV-vis spectrophotometry after incubating our NPs with 97.17 μM H2O2. Using the hydrogen peroxide probe Ti(SO4)2 which becomes lighter with H2O2 decomposition (Fig. S4(c) in the ESM), we were able to determine that within 3 h the PCN-Fe(III) and PCN-Fe(III)-PTX NPs were able to mediate 27.07% and 26.41% H2O2 decomposition, respectively ( Fig. 2(a) in the ESM). In order to further verify the catalytic ability of the PCN-Fe(III) in an oxygen-depleted environment, oxygen concentration at different times was detected by an oxygen dissolving meter, which showed a significant amount of O2 by PCN-Fe(III) and H2O2 mixture ( Fig. S5 in the ESM), consistent with their ability to reduce local hypoxia in the TME.
Based on this promising catalase-like activity, we next investigated the ability of these two NPs to mediate 1 O2 generation via the use of 1,3-diphenylisobenzofuran (DPBF) [35] , which reacted with singlet oxygen to lower the characteristic absorption at 412 nm in the UV spectrum. Following 671 nm laser irradiation (100 mW/cm 2 , 15 min), we found that the PCN-Fe(III) and PCN-Fe(III)-PTX NPs decreased the DPBF UV-vis absorbance spectra to 83.74% and 84.10% of baseline, respectively, within any substantial 1 O2 generation for a control ethanol-DPBF mixture (Fig. 2(b) ). This enhanced 1 O2 generation from these NPs is likely associated with the increased O2 supply generated via the catalase-like reaction assessed above.
Drug release and MRI imaging in vitro
We next measured in vitro cumulative PTX release from the PCN-Fe(III)-PTX NPs at 37 °C in PBS under three different combinations of conditions (pH = 7.4, 5.0, or 5.0 + laser irradiation) (Fig. 2(c) ). At the physiological pH of 7.4, just 22.78% of PTX was released from these NPs, whereas at the more acidic pH of 5.0 this release rate rose to roughly 32.85%, confirming that these NPs mediate pH-dependent drug release that may allow for better chemotherapeutic drug targeting to the acidic TME. Electrostatic repulsions between drugs and nanocarriers as pH decreases is thought to promote such pH-sensitive drug release [36] . When these NPs were both incubated at a pH of 5.0 and underwent laser irradiation (300 mW/cm 2 , 15 min), we observed an even higher drug release rate of 35.84%, consistent with the ability of these NPs to mediate targeted drug release at the tumor site in vivo, minimizing the systemic side effects of chemotherapy. We additionally assessed these PCN-Fe(III)-PTX NPs via TEM following 5 days under these three treatment conditions (Fig. S6 in the ESM), confirming that both lower pH and laser irradiation can promote drug carrier degradation and thereby mediate drug release.
We additionally assessed how these PCN-Fe(III)-PTX NPs performed in vitro using a 1.5 T Micro MR instrument. We observed concentration-dependent T1-weighted MR images ( Fig. 2(d) ), with r1 and r2 values determined via plotting inverse relaxation times (1/T1 and 1/T2) as a function of iron concentrations. As shown in Fig. 2(e) and Fig. S7 in the ESM, the T1 and T2-weighted MR signal intensity for these NPs increased in a linear manner as Fe(III) concentrations rose. We found these PCN-Fe(III)-PTX NPs to have r1 and r2 values of 271.34 and 422.16 mM -1 ·s -1 at 1.5 T, respectively, and the r2/r1 ratio was 1.5558, confirming that PCN-Fe(III) has significant promise for use as a T1-weighted MRI contrast agent.
Cellular uptake, H 2 O 2 degradation and cell inhibition effect in vitro
Prior to further assessing the catalytic potential of PCN-Fe(III) NPs in vitro, we explored the cytotoxicity of these particles through the use of CCK-8 assay, revealing no apparent NP-associated toxicity even at high 100 μg/mL concentrations over a 24 h period when used to treat PANC-1 cells (Fig. S8(a) in the ESM). Even following laser irradiation for 0-15 min (300 mW/cm 2 ), there was no evidence of cytotoxicity ( Fig. S8(b) in the ESM). As such, for further in vitro experiments, laser irradiation was conducted at 300 mW/cm 2 for 15 min. We next utilized CLSM and flow cytometry in order to explore whether PCN-Fe(III) and PCN-Fe(III)-PTX NPs were taken up by cells. To achieve this, we used FITC-phalloidin to stain cell membranes (green), Hoechst dye to stain nuclei (blue), and relied upon the autofluorescent properties of PCN-Fe(III) for detection (red). We were able to clearly observe the presence of both PCN-Fe(III) and PCN-Fe(III)-PTX NPs within cells (Fig. 3) , specifically accumulating in the cytoplasm, as in previous reports [37] . We then used flow cytometry to better quantify these results ( Fig. 4(a) ). When PANC-1 cells were incubated with PCN-Fe(III) and PCN-Fe(III)-PTX NPs for 8 h, we observed a significant increase in mean fluorescence intensity (MFI; 19.57 and 15.9, respectively) relative to PBS controls (1.92), consistent with significant NPs uptake by these cells.
We then assessed H2O2 degradation within cells as a strategy for hypoxia alleviation through the use of the intracellular MAK164 assay ( Fig. 4(b) ). Through this approach, we observed a significant reduction in MAK164 fluorescent signal intensity upon incubation with PCN-Fe(III) and PCN-Fe(III)-PTX NPs, consistent with the degradation of hydrogen peroxide by both of these NPs, making them ideal photosensitizers for PDT in hypoxic environments.
We next conducted an in vitro assessment of the combination efficacy of PCN-Fe(III)-PTX NPs by combining PANC-1 cells with either free PTX, PCN-Fe(III), or PCN-Fe(III)-PTX NPs with or without laser irradiation and measuring cell growth via the CCK-8 assay (Fig. 4(c) ). We observed a trend towards reduced cell viability as NPs concentrations rose, and we observed better therapeutic outcomes in the group simulating PDT + chemotherapy relative to groups receiving either PCN-Fe(III)+laser irradiation or PCN-Fe(III)-PTX alone, confirming that PCN-Fe(III) represents both an ideal drug carrier and PDT agent capable of enhancing PaC cell sensitivity to chemotherapy [38] . Cytotoxicity in cells treated with PCN-Fe(III)-PTX rose significantly upon laser irradiation (300 mW/cm 2 , 15 min). We also assessed cell viability using a Calcein-AM/PI double staining kit, with live cells in green and dead cells in red ( Fig. 4(d) ). Our results revealed that combining PDT and chemotherapeutic drugs was an efficient means of promoting the death of tumor cells, achieving higher efficacy than either treatment on its own.
Pharmacological characteristics and bio-distribution in tumor-bearing mice
Based on the promising combination efficacy observed in vitro, we next explore the use of these PCN-Fe(III)-PTX NPs in vivo. We first explored the relative PCN-Fe(III)-PTX and PTX pharmacological characteristics in mice (Fig. S9 in the ESM) , revealing a significant increasing of the half-life (t1/2) of PCN-Fe(III)-PTX (5.928 h) relative to free PTX (0.549 h). In addition, the maximal plasma PCN-Fe(III)-PTX concentration 3 min following injection was 5.06 times that of free PTX, and PCN-Fe(III)-PTX had an area under the curve (AUC 0-36 h) of 165.554 mg/(mL·h), which was ~ 24.5 times that of free PTX (6.769 mg/(mL·h)). These results thus confirmed that PCN-Fe(III)-PTX significantly increased the circulation time for PTX, therefore representing an ideal means of facilitating NPs accumulation within tumors.
We next used fluorescent imaging and ICP-OES to assess PCN-Fe(III) distribution in vivo, revealing significantly higher autofluorescence in mice injected with PCN-Fe(III) after 24 h than in PBS-injected controls ( Fig. 5(a) ). After 28 h, primary organs and tumors were resected from mice, revealing the presence of significant tumoral PCN-Fe(III) NPs accumulation ( Fig. 5(b) ). We additionally explored the in vivo imaging potential of these particles by imaging mice 24 h following NPs i.v. injection using a 1.5 T human clinical MR scanner. We observed a significantly brighter signal in mice administered PCN-Fe(III)-PTX than in those treated with PBS as a control (Fig. 5(c) ), with a relative tumor T1 value increase of 24.13% (1216.5/922.9), consistent with these NPs being ideal for monitoring PDT efficacy via T1-MR imaging in mice bearing PANC-1 tumors. We additionally used aqua regia to digest tumor tissues and organs at particular time points post-injection in order to assess Fe ion levels via ICP-OES ( Fig. 5(d) ). Through this approach, we observed a significant increase in Fe(III) ion levels in the tumor over time, peaking at 0.58 mg/g at 24 h post-injection, suggesting that tumor irradiation at this time point will yield the best PDT efficacy.
In vivo pharmacokinetics and antitumor efficacy
In light of this optimal PCN-Fe(III) intratumoral enrichment, we next explored the PDT efficacy of these PCN-Fe(III)-PTX NPs in mice bearing PANC-1 tumors. Mice were randomized into 5 different treatment groups (PBS, free PTX, PCN-Fe(III)-PTX, PCN-Fe(III)+laser, and PCN-Fe(III)-PTX+laser) and treated as indicated, with laser irradiation being performed, where appropriate with the following conditions 24 h postinjection: 15 min, 671 nm, 300 mW/cm 2 . In PBS control mice, tumors grew rapidly ( Fig. 6(a) ), while PCN-Fe(III)-PTX achieved better anti-tumor efficacy than free PTX, confirming that these NPs represent an effective drug carrier well-suited to tumorspecific drug delivery. Mice administered PCN-Fe(III) plus laser irradiation exhibited partial tumor regression as a result of PCN-Fe(III)-mediated PDT, but tumors began to recur within 6 days. In contrast, we observed much better combination efficacy in mice in the PCN-Fe(III)-PTX + laser irradiation group, with 4 mice exhibiting complete tumor regression and one mouse exhibiting recurrence on day 6. After 16 days, we euthanized mice and collected the tumors, revealing tumor masses ( Fig. 6(b) ) which were consistent with tumor growth curves. We also monitored body weight in these mice over time to determine whether any systemic toxicity was associated with PCN-Fe(III)-PTX treatment (Fig. 6(c) ). No significant differences in weight were observed among groups, confirming that these NPs do not mediate significant toxicity in these animals, making them well-suited to therapeutic tumor treatment efforts. We additionally photographed mice on days 0, 8, and 16, and analyzed tumors via H&E staining 24 h after treatment ( Fig. 6(d) ).
In a final experiment, we conducted routine blood and histology analyses to assess any long-term PCN-Fe(III)-PTX toxicity in vivo. We collected blood from mice via retro-orbital bleeding in a longitudinal manner following PCN-Fe(III)-PTX injection, analyzing a number of standard blood parameters including: white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell volume distribution width (RDW), platelet counts (PLT), mean platelet volume (MPV), platelet hematocrit (PCT), platelet distribution width (PDW) ( Fig. 7(a) ), and biochemical analysis (Figs. 7(b) and 7(c)). For all treated mice we observed normal values for all of these indexes over a 21 days treatment period, confirming that PCN-Fe(III)-PTX induces negligible toxicity in vivo. When mice were euthanized on day 21 and histological analysis was conducted ( Fig. 7(d) ), we detected no significant evidence of tissue damage or inflammatory lesions, additionally illustrating that these PCN-Fe(III)-PTX NPs achieve high histocompatibility.
Together these results confirm that PCN-Fe(III)-PTX NPs mediate no significant systemic toxicity, highlighting their promise as a future therapeutic platform.
Conclusions
In conclusion, through a two-step process we were able to successfully synthesize mesoporous PCN-Fe(III)-PTX NPs that were capable of delivering chemotherapeutic drugs, serving as PDT photosensitizers, and mediating Fenton-like reactions in tumors. These mesoporous PCN-Fe(III)-PTX NPs were able to load PTX with a high degree of efficiency, readily enriched in tumors, and were able to release this drug in a pH-and laser-responsive fashion, thus offering an optimal system for tumor drug delivery. Both in vitro and in vivo results confirmed that these particles were able to overcome local tumor-associated hypoxia via generation of O2 owing to a reaction between endogenous H2O2 and the PCN-Fe(III)-PTX NPs, with the PCN-Fe(III)-PTX platform thereby markedly enhancing PDT therapeutic efficacy in hypoxic tumors. In addition, the iron ions present within PCN-Fe(III) make these NPs ideal as MRI contrast agents suitable for detecting and monitoring tumor responses over the course of PDT treatment. As such, these biocompatible PCN-Fe(III)-PTX NPs represent ideal theranostic agents with the potential to greatly improve the treatment efficacy of PaC and other cancer in patients. 
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